CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value
Journal for ImmunoTherapy of Cancer · 2024
DOI: 10.1136/jitc-2023-007939 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Francesca Battaglin und 28 weiteren Autor:innen. Beteiligte Einrichtung: University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA fbattagl@usc.edu. Hauptthemen laut MEDLINE: Receptors, Chemokine, Colorectal Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Pfizer, Dhont Family Foundation.
Abstract (Originalsprache)
Background
The C-C motif chemokine receptor 5 (CCR5)/C-C motif chemokine ligand 5 (CCL5) axis plays a major role in colorectal cancer (CRC). We aimed to characterize the molecular features associated with CCR5 / CCL5 expression in CRC and to determine whether CCR5 / CCL5 levels could impact treatment outcomes.
Methods
7604 CRCs tested with NextGen Sequencing on DNA and RNA were analyzed. Molecular features were evaluated according to CCR5 and CCL5 tumor gene expression quartiles. The impact on treatment outcomes was assessed in two cohorts, including 6341 real-world patients and 429 patients from the Cancer and Leukemia Group B (CALGB)/SWOG 80405 trial.
Results
CCR5 / CCL5 expression was higher in right-sided versus left-sided tumors, and positively associated with consensus molecular subtypes 1 and 4. Higher CCR5 / CCL5 expression was associated with higher tumor mutational burden, deficiency in mismatch repair and programmed cell death ligand 1 (PD-L1) levels. Additionally, high CCR5 / CCL5 were associated with higher immune cell infiltration in the tumor microenvironment (TME) of MMR proficient tumors. Ingenuity pathway analysis revealed upregulation of the programmed cell death protein 1 (PD-1)/PD-L1 cancer immunotherapy pathway, phosphatase and tensin homolog (PTEN) and peroxisome proliferator-activated receptors (PPAR) signaling, and cytotoxic T-lymphocyte antigen 4 (CTLA-4) signaling in cytotoxic T lymphocytes, whereas several inflammation-related pathways were downregulated. Low CCR5 / CCL5 expression was associated with increased benefit from cetuximab-FOLFOX treatment in the CALGB/SWOG 80405 trial, where significant treatment interaction was observed with biologic agents and chemotherapy backbone.
Conclusions
Our data show a strong association between CCR5/CCL5 gene expression and distinct molecular features, gene expression profiles, TME cell infiltration, and treatment benefit in CRC. Targeting the CCR5/CCL5 axis may have clinical applications in selected CRC subgroups and may play a key role in developing and deploying strategies to modulate the immune TME for CRC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA fbattagl@usc.edu.
- Caris Life Sciences, Phoenix, Arizona, USA.
- Department of Population and Public Health Sciences, University of Southern California Keck School of Medicine, Los Angeles, California, USA.
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
- Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA.
- University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Francesca Battaglin, Hiroyuki Arai, Emil Lou, Heinz-Josef Lenz
Förderung
- NCI NIH HHS
- Pfizer
- Dhont Family Foundation
- Victoria and Philip Wilson Research Fund
- San Pedro Peninsula Cancer Guild
- Gloria Borges WunderGlo Foundation
- Ming Hsieh Research Fund
- National Cancer Institute
Zitieren
APA
Battaglin, F., Baca, Y., Millstein, J., Yang, Y., Xiu, J., Arai, H., Wang, J., Ou, F. S., Innocenti, F., Mumenthaler, S. M., Jayachandran, P., Kawanishi, N., Lenz, A., Soni, S., Algaze, S., Zhang, W., Khoukaz, T., Roussos Torres, E., Seeber, A., …, & Lenz, H. J. (2024). CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2023-007939
Vancouver
Battaglin F, Baca Y, Millstein J, Yang Y, Xiu J, Arai H, et al. CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2023-007939
BibTeX
@article{Battaglin2024,
author = {Battaglin, Francesca and Baca, Yasmine and Millstein, Joshua and Yang, Yan and Xiu, Joanne and Arai, Hiroyuki and Wang, Jingyuan and Ou, Fang-Shu and Innocenti, Federico and Mumenthaler, Shannon M and Jayachandran, Priya and Kawanishi, Natsuko and Lenz, Annika and Soni, Shivani and Algaze, Sandra and Zhang, Wu and Khoukaz, Taline and Roussos Torres, Evanthia and Seeber, Andreas and Abraham, Jim P and Lou, Emil and Philip, Philip A and Weinberg, Benjamin A and Shields, Anthony F and Goldberg, Richard M and Marshall, John L and Venook, Alan P and Korn, W Michael and Lenz, Heinz-Josef},
title = {CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
doi = {10.1136/jitc-2023-007939}
}
EUVIMED